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Reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) is achieved by viral-mediated transduction of deﬁned
transcription factors. Generation of iPSCs is of great medical interest as they have the potential to be a source of patient-speciﬁc
cells. For the eventual goal of clinical application, it is necessary to overcome the limitations of low reprogramming eﬃciency
and chromosomal abnormalities due to viral DNA integration. In this paper, we summarize the current state of reprogramming
technology for generation of iPSCs and also discuss potential approaches to the development of safe iPSCs for personalized cell-
based replacement therapy.
1.Introduction
Embryonic stem cells (ESCs), which are derived from the in-
ner cell mass of blastocyst stage embryos, have the unique
ability to self-renew indeﬁnitely as well as the capability to
diﬀerentiate into three germ lineages, which eventually give
rise to the various cell types of the human body [1, 2]. Hu-
man embryonic stem cells can provide a potential source of
cells for cell replacement therapy and/or drug discovery for
the treatment of disastrous disorders, but there are limita-
tions that must be overcome, such as immune rejection and
ethical issues surrounding the use of human embryos as an
ESC source, for hESCs to be used clinically [3].
Celldiﬀerentiationintospeciﬁccelltypesisconsideredto
be unidirectional, as cell reprogramming has been rarely ob-
served [4, 5]. However, nuclear transfer and cell fusion ex-
periments have demonstrated that somatic cells could be re-
programmed into a pluripotent embryonic cell state through
the epigenetic modiﬁcations [6, 7] while these technologies
still require the use of embryos.
A major advance in the stem cell ﬁeld was the conversion
of somatic cells to an embryonic stem cell state, which was
named as induced pluripotent stem cells (iPSCs), using
deﬁned transcription factors by Yamanaka and colleagues in
2006and2007.iPSCscanavoidimmunerejection,sincecells
are derived from a patient’s own cells, as well as any ethical
issues regarding the use of human embryos. The characteris-
ticsofiPSCsarealsoverysimilartothoseofpluripotentESCs
in many aspects, including cell morphology, expression of
pluripotent markers, patterns of epigenetic changes, and
capability to form embryoid bodies, teratoma, and viable
chimeras [8]. However, there are still a number of problems
related to current reprogramming methods. The use of viral
vectors has led to the integration of multiple viruses into
iPSC genomes, resulting in tumorigenesis due to genetic ab-
normalities in the cells. The reprogramming eﬃciency of hu-
man iPSCs from ﬁbroblasts is very low, approximately less
than0.02%[9].TheuseofMycgeneasareprogrammingfac-
tor and/or the reactivation of a silenced Myc gene might
cause iPSCs to become cancer cells. The kinetics for repro-
gramming of human iPSCs are also very slow, taking more
than 3 weeks approximately [10]. Both the low eﬃciency and
slow kinetics of iPSC reprogramming may result in genetic
alterations that aﬀect the pluripotent and diﬀerentiation2 The Scientiﬁc World Journal
properties of iPSCs and ESCs. Addressing these concerns is
already a top priority in this ﬁeld.
Many groups have designed more eﬃcient and safer re-
programming methods for iPSC generation than Yamanaka’s
protocol. In this paper, we summarize various reprogramm-
ing methods and also discuss the main approaches to ach-
ieving safe iPSC generation for regenerative medicine.
2.ReprogrammingbyNuclearTransfer
Nuclear transfer constitutes a proof of principle that rever-
sible genomic alterations are required for normal develop-
ment. However, since there were no factors reported in pre-
vious reprogramming studies, there remains a question as to
whether or not terminally diﬀerentiated cells can be repro-
grammed into a totipotent state. The successful generation
of genetically identical mouse clones by somatic cell nuclear
transfer (SCNT) technology from various mature cell types
[11–13] has demonstrated that terminally diﬀerentiated cells
have the nucleus potential to support development. Impor-
tantly, the reprogramming of somatic donor cells using
SCNT also has revealed that unfertilized eggs contain pluri-
potent genes [14]. Cloning from terminally diﬀerentiated
donor cells is ineﬃcient, with successes coming only when
cloned ESCs are used. Binucleate hybrid cells produced by
cell fusion of embryonic cells with somatic cells have been
used to demonstrate the epigenetic reprogramming of soma-
tic cells to a pluripotent state. Mouse and human hybrid cells
produced by fusion between various somatic cells and em-
bryonic carcinoma cells [15], embryonic germ cells [16]o r
ESCs [7, 16, 17] share the same phenotype and gene expres-
sion pattern as parental embryonic cells, which indicates that
ESCs express dominant pluripotent factors for reprogram-
ming of somatic cells. Therefore, nuclear reprogramming
studies using SCNT and cell fusion have demonstrated that
transcriptionalfactorsareessentialforthereprogrammingof
terminally diﬀerentiated cells.
3.ReprogrammingbyDeﬁned
TranscriptionFactors
In 2006, Takahashi and Yamanaka achieved a breakthrough
in the reprogramming of somatic cells to a pluripotent ESC-
like state through the transduction of retroviral vectors con-
taining 24 candidate genes into mouse ﬁbroblasts. The pool
ofgeneswasﬁnallynarroweddowntofourtranscriptionfac-
tors, Oct3/4, Sox2, c-Myc, and Klf4, which were transduced
into mouse ﬁbroblasts containing a fusion cassette of the
β-galactosidase and neomycin resistance genes downstream
of the Fbx15 gene promoter. The transcription factors were
already known to contribute to the self-renewal of pluripo-
tent ESCs. The Oct-4(Pou5f1) gene, named as Octamer
(ATGCA/TAAT)-binding protein-4, encodes a transcription
factor that belongs to the class of POU factors (known as
Pit1, Oct1, Oct2,a n dUnc86), which have a bipartite DNA-
binding domain [40]. Oct4 is known to be required for the
formation of the inner cell mass in early embryos and for the
maintenance of the pluripotency of ESCs [41–43]. Oct4 can
alsoformahomodimerbyitselfaswellasaheterodimerwith
Sox2, and its cooperative binding with Sox2 promotes the
transcriptional regulation of various target genes such as
Nanog [44]. Interestingly, although Scholar’s group demon-
strated that Oct4 alone can reprogram mouse and human
neural stem cells to iPSCs [45–47], a two-factor combination
of Oct4 and Sox2 or a three-factor combination of Oct4,
Sox2, and Klf4 is still required for iPSC generation in most
somatic cell types. The Sox2 gene, designated as SRY- (Sex-
determining Region Y-) box2, encodes a transcription factor
belonging to the Sox family of proteins, which bind to DNA
through their 79-amino-acid HMG domain [48]. The Klf4
gene, named as Kr¨ uppel-like zinc-ﬁnger protein 4,e n c o d e s
a transcription factor and is known to be required for esta-
blishment of left-right asymmetry in early embryos. Klf4 can
also directly bind to the Oct4-Sox2 heterodimer in mouse
ESCs, and tetrameric complexes containing the DNA ele-
mentofatargetgenearerequiredforsomaticcellreprogram-
ming [49]. The c-Myc gene, named as cellular homolog of
retroviral v-myc oncogene, encodes a transcription factor
containing a basic helix-loop-helix/leucine zipper domain.
c-Myc binds to DNA through its bHLH motif and hetero-
dimerizes with other interacting proteins through its leucine
zipper motif. c-Myc is involved in the maintenance of pluri-
potent ESCs through signaling [50] and promotes cell pro-
liferation by inducing global histone acetylation by histone
acetyltransferases (HATs). Other groups have reported that
only the three transcription factors Oct4, Sox2, and Klf4 can
successfully generate iPSCs from mouse and human ﬁbrob-
lasts [51], indicating that c-Myc is not decisively essential
for direct reprogramming of somatic cells into iPSCs. iPSCs
derived from these three factors do not develop into cancer
cells, which is counter to a report that cancer developed in
20% of chimeric mice [52]. The use of subtypes of transcrip-
tion factors was used successfully to generate iPSCs from
somatic cells, although reprogramming eﬃciency was aﬀect-
ed; Sox2 can be replaced by Sox1 and Sox3, c-Myc can be
replaced by L-Myc and N-Myc, and Klf4 can be replaced by
Klf2 [51, 53]. Thomson’s group used a diﬀerent set of tran-
scription factors containing additional two reprogramming
factors such as Nanog and Lin28 to reprogram human ﬁbro-
blasts[23].TheNanog gene,namedafterT´ ırnan ´ Og,encodes
a transcription factor containing a conserved NK2-family
homeodomainmotif.Nanogisexpressedinpluripotentstem
cellsandisinvolvedincellproliferationandmaintainingself-
renewal of ESCs [54]. Nanog can also assemble into homo-
dimers with itself through a specialized tryptophan-rich C-
terminal domain for the cooperative regulation of target
genes [55, 56]. Lin28 (Lin-28 homolog A) encodes a cyto-
plasmic mRNA-binding protein that can drive speciﬁc
mRNAs to translational machinery for the enhancement of
protein synthesis [57]. In order to reprogram mature cells
into iPSCs, many modiﬁed reprogramming protocols using
diﬀerent combinations, diﬀerent subtypes, and diﬀerent sets
of transcription factors have been used to date. However,
we need to realize that some of these factors are oncogenes,
which may cause tumor formation in the form of oncogene-
derived iPSCs.The Scientiﬁc World Journal 3
Table 1: Methods of eﬃcient and safe iPSCs generation for clinical applications.
Methods Advantage Disadvantage Species Eﬃciency
(%) Safety References
Retroviral vectors Dividing cell infection,
moderate eﬃciency
Multiple integration,
incomplete silencing,
tumorigenicity possible
P ,R ,R h ,M ,H 0 . 0 1 ∼0.5 No good [18–21]
Lentiviral vectors
Dividing or nondividing
cell infection, moderate
eﬃciency
Multiple integration,
incomplete silencing,
tumorigenicity possible
M, H 0.1∼1 No good [22, 23]
Induced lentiviral
vectors
Tight transcriptional
regulation, dividing or
nondividing cell infection,
moderate eﬃciency
Multiple integration,
transactivator needed,
tumorigenicity possible
P, M, H 0.1∼1 No good [24–26]
Adenoviral vectors Nonintegration Integrated vector-fragment
possible, low eﬃciency M, H ∼0.001 Good [27]
Sendaiviral vectors
Transgene decreased during
cell division,
nonintegration, easy to
remove Sendaivirus
Integrated vector-fragment
possible H 0.001∼1 Good [28]
Plasmids Simple transfection Occasional integration, low
eﬃciency M, H ∼0.001 Good [29]
Plasmids +
Nanoparticles
Rapid and simple
transfection
Occasional integration, low
eﬃciency M 0.001∼
0.003 Good [30]
oriP/EBNA-1 episomal
vectors
Nonintegrating vector,
long-term persistent
transcription
Extremely low eﬃciency H ∼0.0003 Good [31]
Cre/loxP recombination
systems
Integration but excisable,
dividing or nondividing
cell infection
Ineﬃcient loxP site
excision, screening needed,
tumorigenicity possible
H0 . 1 ∼1 No good [32]
Piggyback transpo-
son/transposase system
Precise excision possible,
moderate eﬃciency Screening needed, M, H ∼0.1 Good [33, 34]
Minicircle DNA
episomal vectors
Improved eﬃciency,
nonintegration Low eﬃciency H ∼0.005 Good [35]
Proteins DNA-free
Extremely low eﬃciency,
long-term treatment
required, genetic
abnormality possible
M, H ∼0.001 Very good [36, 37]
R N A s D N A - f r e e ,H i g he ﬃciency Multiple transfection H ∼1 Very good [38]
F a c t o r s+S m a l l
molecules High eﬃciency
Long-term treatment
required, abnormal
signaling pathway possible,
virus used
M, H ∼2.05 No good [39]
Pig (P); rat (R); rhesus monkey (Rh); mouse (M); human (H).
4.ReprogrammingTechnologies
The choice of a gene delivery system is a key aspect for iPSC
generation. Many researchers in this ﬁeld still use viral or
nonviral methods to reprogram mature cells (Figure 1), and
some groups have tried to use nongenetic materials for the
generation of eﬃcient and safe iPSCs (Table 1).
4.1. Integration Viral Vector Systems. For the initial genera-
tion of iPSCs, retroviral vectors as a powerful gene delivery
system have been used to introduce the four transcription
factors into ﬁbroblasts. Retroviral vectors can be eﬃciently
transduced into target cells and randomly integrated into the
host genome of only dividing cells. Although retroviral vec-
tors have higher eﬃciency of transduction than that of other
v i r a lv e c t o r sw i t h o u ta n ys e v e r ee ﬀects on cell viability, the
expression of integrated genes could become silenced during
the epigenetic processes of gene regulation, which provides
an advantage in that the temporal expression of exogenous
factors may be required for the generation of iPSCs. As ano-
ther gene delivery system for the generation of iPSCs, lenti-
viral vectors have been used. Lentiviral vectors as a subclass
of retroviruses can also be integrated into the host genome
of both dividing and nondividing cells, which means that
lentiviralvectorscanbeappliedtoawidevarietyofcelltypes.
In addition, advanced inducible-lentiviral vector systems us-
ing doxycycline as an inducer have been used for the speciﬁc
control of the expression of the four transcription factors4 The Scientiﬁc World Journal
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Figure 1: strategies for generation of somatic cells into induced pluripotent stem cells (iPSCs) using diﬀerent gene delivery systems.
and for high eﬃciency of fully reprogrammed iPSCs during
induction [27, 58–60]. Although eﬃcient gene delivery sys-
tems using retroviral and/or lentiviral vectors have been used
to introduce reprogramming factors into somatic cells, these
viral vector systems remain controversial due to multiple
copies of proviral genomic integration, which may cause
both the reactivation of silenced exogenous oncogenes such
as Klf4 and c-Myc and the alteration of genomic construc-
tion, thereby increasing the risk for malignant cancer trans-
formation [60]. Eﬀorts for the practical use of iPSCs in cli-
nical applications have led to the technical development of
nonintegration viral vectors or DNA approaches.
4.2. Integration-Free Viral Vectors and DNA Systems
4.2.1. Viral Vectors. Using an adenoviral vector as a dsDNA
virus, which is a nonintegration vector that remains in epi-
chromosomal form in cells, virus-free iPSCs have been suc-
cessfully generated, although with low eﬃciency [27, 59, 60].
In addition, since the adenoviral vector system gives rise to
only transient expression, it may require the repeated deliv-
ery of reprogramming factors during induction of iPSCs.
However, the success of nonintegrating iPSC generation sug-
gests that the integration of transcription factors into
the genome is not required for the reprogramming of soma-
tic cells, providing the potential to develop nonviral delivery
technologies that could be used to generate safe iPSCs. As
another viral vector system without genomic integration,
Sendaiviral (Sendaivirus) vector, which is an RNA virus that
replicates its genome exclusively in the cytoplasm, eﬃciently
generated iPSCs from human somatic cells [28]. Nonethe-
less, iPSC research is moving toward the development of new
technologies without genetic modiﬁcation.
4.2.2. Plasmid DNA and Transfection. An o n v i r a ls y s t e mi s
transfectiontechnology thatusescomplexes ofplasmidDNA
carrying reprogramming factors and lipid or cationic poly-
mers that are then introduced into the cells to be reprogram-
med. Plasmid DNA is not usually integrated into the host
genome and exhibits gene expression after 2-3 days. Okita
et al. reported the ﬁrst successful generation of iPSCs from
mouseandhumanﬁbroblastsbyrepeatedtransfectionoftwo
expression plasmids in a nonviral vector system, one ex-
pressingOct4,Sox2,andKlf4andtheotherexpressingc-Myc
[61]. Most iPSC lines generated by this method are free from
DNA integration into the host genome, even though plasmid
DNA integration in some lines has been detected at rates as
low as approximately 5.5%. The advantage of this method isThe Scientiﬁc World Journal 5
the generation of iPSCs without plasmid DNA integration at
a rate as high as 60%, indicating reproducibility of the trans-
fectiontechnique.However,theeﬃciencyofiPSCgeneration
is substantially lower than that of viral systems using retro-
viral or lentiviral vectors, which may be due to lower trans-
fection eﬃciency or transgene expression levels [29]. Ano-
ther group successfully generated iPSCs without any plasmid
DNA integration from mouse embryonic ﬁbroblasts using
a single plasmid DNA containing all four factors through
nucleofection transfection technique, which is based on the
electroporation method generated by a Nucleofector device
[62]. Unlike regular plasmid vectors, oriP/EBNA1 episomal
plasmid vectors derived from Epstein-Barr virus can be
transfected without the need for viral packaging, although
they can be replicated only once per cell cycle [63, 64]. This
vector can be established as a stable episome in transfected
cells through drug selection, but it is not capable of integra-
tion into the host cell genome [31, 65, 66]. If drug selection
is absent, the vectors are gradually lost at rate of a 5% during
celldivision duetodefectsinplasmid synthesis, whichallows
cells lacking plasmids to be easily isolated [67]. Junying
et al. successfully generated the ﬁrst human iPSCs using an
oriP/EBNA1 episomal plasmid containing reprogramming
factors, but reprogramming eﬃciency was extremely low (3
to 6 colonies per 106 input of cells) [31]. Recently, Jia et al.
reported the successful generation of iPSCs from adult hu-
man adipose-derived stem cells (ADSCs) by nucleofection of
minicircle vector DNA. The minicircle vectors are supercoil-
ed DNA molecules devoid of any bacterial plasmid DNA
backbone. Their smaller molecular size allows for more eﬃ-
cient transfections and oﬀers sustained expression over a
period of weeks as compared to regular plasmid vectors,
which only work for a few days [35]. However, the overall re-
programming eﬃciency is very low (approximately 0.005%).
Very recently, our group successfully generated DNA-free
iPSCsmagneticallybyintroducingcomplexesofregularplas-
mid DNA containing each factor and nanoparticles into
mouse ﬁbroblasts, although some iPSC lines were detected
withgenomicintegrationoftheplasmidDNAandtherepro-
gramming eﬃciency was relatively low [30].
4.2.3. Excision of Integrated Transgenes. There are two sys-
tems that use either Cre/loxP recombination or piggyBac
transposition for the removal of exogenous reprogramming
factors from genomic integration sites in iPSCs. In the Cre/
loxP recombination system, a loxP site is inserted into the 3 
long-term repeat (LTR) of self-inactivating (SIN) lentiviral
vectors containing reprogramming factors under the control
of a doxycycline- (Dox-) inducible minimal cytomegalovirus
(CMV) promoter [68]. The loxP is duplicated into the
5 LTR during proviral replication, resulting in host genomic
integration with a transgene ﬂanked by two loxP sites. The
lentiviral vector system has been used to generate iPSCs with
multiplecopiesofgenomicintegration,afterwhichtheiPSCs
are transiently transfected with an expression vector encod-
ing Cre recombinase and the puromycin resistance gene by
electroporation, thus enabling the excision of all reprogram-
ming factors [68–70]. Although the resulting factor-free
iPSCs show a similar gene expression proﬁle as that of ESCs
rather than that of the preexisting iPSCs, the Cre-mediated
excision protocol leaves behind a loxP and vector DNA frag-
ment in the iPSCs that can result in genomic instability and
genome rearrangements. To address these multiple genomic
integrations, Shao et al. developed a single plasmid vector
system with a 2A-peptide-linked reprogramming cassette
originating from the foot-and-mouth disease virus of the
Picornaviridae family to generate virus-free, factor-remov-
able iPSCs [33, 71]. The multiprotein expression system was
shown to minimize genome modiﬁcation in iPSCs and in-
crease reprogramming eﬃciency, but it still displayed the
same problems as the Cre/loxP recombination system. As an
alternative strategy to excise remaining exogenous DNA,
Yusa et al. recently used the piggyBac (PB) transposon/trans-
posase system, which is capable of removing itself precisely
from cells, to successfully generate iPSCs bearing a single
integration site from somatic cells [34]. The PB plasmid vec-
tor was constructed with 2A peptide-linked reprogramming
factors under the control of the tetO tetracycline/doxycline
inducible promoter, which was inserted between PB 5  and
3  terminal repeats. Moreover, the original integration sites
were subsequently excised from the iPSCs at a rate of high-
er than 90% by transient expression of PB transposase.
O’Malley et al. also used PB-based vectors constructed with
puΔtk cassette as a negative selection marker and 2A pep-
tides-linked reprogramming factors under the control of the
CAG promoter to eﬃciently generate integration-free iPSCs
from mouse ﬁbroblasts after transient PB treatment [72].
However, these excision approaches are complex and time-
consumingsincetheyrequiretheidentiﬁcationofiPSCswith
minimal-copy insertions, mapping of integration sites, exci-
sion of the reprogramming cassette, and validation of factor-
free clones [73].
5. Approaches to Enhancementof
Reprogramming Efﬁciency
Despite the successful generation of iPSCs using reprogram-
ming factors, the slow and ineﬃcient nature of the repro-
gramming process initially limited the generation of iPSCs as
well as their potential clinical application. However, a num-
ber of groups recently reported studies on the improvement
of reprogramming eﬃciency using diﬀerent reprogramming
factors either alone or in combination with chemicals. Park
et al. increased reprogramming eﬃciency approximately 3-
fold using SV40 large antigen (SV40LT) and human telom-
erase reverse transcriptase (hTERT) as additional factors in
combination with Oct, Sox2, Klf4, and c-Myc (OSKM)
[74, 75]. Maekawa et al. increased reprogramming eﬃciency
about 70-fold using a diﬀerent combination of transcription
factors such as SV40 TL, Oct4, Sox2, Nanog, and Lin28 [76].
Very recently, Zhao et al. observed that the Gli-like transc-
ription factor Glis1 (Glis family zinc ﬁnger 1) markedly en-
hanced the generation of iPSCs from mouse and human
ﬁbroblasts transduced with three factors (OSK) [77]. Strik-
ingly, human ﬁbroblasts transduced with lentiviral vectors
containing OSKM, p53 siRNA, and UTF1 previously showed6 The Scientiﬁc World Journal
more than 100-fold enhancement of reprogramming eﬃ-
ciency as compared to those transduced only with OSKM. In
addition, when p53 siRNA and UTF1 were added to a com-
bination of three factors (OSK), the reprogramming eﬃcien-
cy increased 100-fold compared to treatment with only OSK
[78, 79]. These data suggest that UTF1, which is known to
be a target of the Oct4-Sox2 heterodimer [80], can
activate other important downstream genes for repro-
gramming [78, 79]. As an explanation, p53 loss may enhance
reprogramming eﬃciency through stimulation of cell cycle
progression by inhibiting both cell death and senescence,
but there is a risk that the iPSCs are abnormal since p53 is
known to play a crucial role in the maintenance of geno-
mic integrity. Recently, these suggestions have been demon-
strated experimentally and the roles of p53 were actively
described during the reprogramming process [81–87]. How-
ever, Mikkelsen et al., who used pre-B cells derived from
NGFP1 iPSCs, which had been transduced with p53 siRNA,
reported that the key parameter of reprogramming eﬃciency
is the number of cell divisions [88]. A combined approach
using transient p53 suppression with reprograming factors
in an integration-free delivery system [61] or with chemicals
known to modulate genome-wide chromatin structure and
gene activities [89–91] was previously shown to increase re-
programming eﬃciency for therapeutic use.
Besides reprogramming factors and chemicals as epige-
neticmodiﬁers,themicroRNAs(miRNAs)areknowntoplay
an important role in the reprogramming process and eﬃ-
ciency [92]. Recently several groups eﬃciently generated
iPSCs from mouse and human ﬁbroblasts using miRNAs
[93,94].Inaddition,Zhouetal.showedthatthemiR302/367
cluster eﬃciently can reprogram mouse and human ﬁbrob-
lasts into an iPSC state without using any reprogramming
factors [95]. However, all of the iPSCs made using either
miRNAs alone or in combination with the four factors were
integrated by retroviral or lentiviral vectors.
6. Approaches for Safe and Efﬁcient
Reprogramming
All the methods that have been used to date still involve the
useofgenetictranscriptionfactors,whichcouldcausepoten-
tial risks of tumorigenesis. However, various approaches to
avoid the introduction of exogenous genetic factors to target
cells have been also developed as discussed above, and recent
studies have provided attractive methods using reprogram-
ming proteins, mRNAs, and chemicals to address safety
concerns.
Two groups demonstrated that puriﬁed recombinant re-
programming factor proteins fused with a polyarginine cell-
penetrating peptide (CPP) can successfully generate iPSCs
from mouse and human ﬁbroblasts [45–47, 96]. Ever since
trans-activating transcriptional activator (TAT) peptide was
ﬁrstisolatedfromhumanimmunodeﬁciencyvirus1(HIV-1)
in 1988 [97], CPP technology has been used to promote the
cellular uptake of molecular cargos, such as small chemical
molecules, DNAs, or proteins. Frankel and Pabo transduced
reprogramming proteins into target cells for four cycles
overnight in combination with valproic acid (VPA) and an
HDAC inhibitor, followed by 36 additional hours of cultur-
ing, after which the treated cells were transferred into irrad-
iated feeder cells and kept in ESC media until three iPSC
colonies formed between days 30 to 35 [96]. Kim et al. trans-
ducedreprogramingproteinsforsixcyclesover16hours,fol-
lowedby6daysofculturing,andsuccessfullyestablishedtwo
iPSC lines out of ﬁve colonies isolated on day 56 [45–47].
Although the protein-based reprogramming approach suc-
cessfully generated iPSCs that were not integrated by any
genetic factors, the reprogramming process was very slow
and eﬃciency was very low, causing some changes in geno-
mic integrity. In addition, the requirement for the multiple
transduction of reprogramming factor proteins hampered
the reprogramming process.
Yisraeli and Melton generated iPSCs using mRNAs of
the reprogramming factors that were synthesized by in vitro
transcription (IVT) of the PCR amplicons and then addi-
tionally modiﬁed with a cap analog and poly-A tail to pro-
mote the initial binding of ribosomes and mRNA stability in
the cytoplasm [38, 98]. Although this synthetic RNA-based
approach safely and eﬃciently induced iPSCs, it was techni-
cally complex with multiple transfections required. Another
alternative approach to safely improve the reprogramming
process for the generation of iPSCs is to use a cocktail of
smallmoleculesthatarelinkedwithepigeneticmodiﬁersand
major signaling pathways. Inhibitors of histone deacety-
lases (HDACs), histone demethylases (HDMs), and his-
tone methyltransferases (HMTs), which regulate chromatin
remodeling, have been identiﬁed as small molecules for
reprogramming somatic cells into iPSCs. HDAC inhibitors
such as VPA, trichostatin A (TSA), and suberoylanilide
hydroxamic acid (SAHA) signiﬁcantly were shown to im-
prove reprogramming eﬃciency. In particular, VPA treat-
ment greatly improved reprogramming eﬃciency by more
than 100-fold in four factor-infected MEFs hemizygous for
the Oct4-GFP transgene as a reporter [99]. The Wnt sig-
naling pathway is involved in promoting self-renewal of
ESCs through inhibition of GSK-3β and subsequent nuclear
accumulation of β-catenin [100]. Interestingly, when Dox-
inducible OSK-MEFs were previously treated with Wnt3a-
conditioned medium, reprogramming eﬃciency increased
by as much as 20-fold [101]. Lin et al. reported that inhibi-
tion of GSK-3β using CHIR99021 signiﬁcantly improved the
reprogramming eﬃciency of MEFs transduced with three
factors (OSK) [102]. In addition, Takahashi reported that
combined inhibition of the TGFβ and MEK-ERK pathways
using SB-431542 and PD-0325901, respectively, not only im-
proved the eﬃciency of the reprogramming process but also
accelerated kinetics. When a cocktail of SB-431542 and PD-
0325901 including thiazovivin, which improves the survival
of human ES cells upon trypsinization (unpublished data by
Ding’s group), was treated to human ﬁbroblasts transduced
with the four factors, the eﬃciency of the reprogramming
process was dramatically improved more than 200-fold [39].
However, there still remain safety concerns in terms of
more subtle and harmful endogenous genetic and epigenetic
alterations that may occur during reprogramming of iPSCs,
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suppressor pathways could be also inhibited after using a
small molecule or a cocktail of small molecules.
7. Conclusion
The reprogramming of somatic cells into pluripotent cells
was originally achieved by transduction of retroviral vectors
containing four transcription factors into mouse and human
ﬁbroblasts [9, 25, 60, 102]. Although recent studies have
shown signiﬁcant technical progress in improving repro-
gramming, simple and eﬃcient reprogramming approaches
are still strongly required. In addition, the development of
technology to generate iPSCs for clinical applications should
address these safety concerns.
The iPSC ﬁeld should focus more on both the develop-
ment of more advanced reprogramming technologies that
employ a nonintegrating vector carrying a minimal set of re-
programming factors and the identiﬁcation of new small
molecules that modulate the reprogramming process. The
combinatorial action of epigenetic or signaling modiﬁers
with nonintegrating delivery systems containing reprogram-
ming factors could be a powerful approach to generate more
eﬃcient and safer iPSCs. However, it still remains a challenge
to reprogram somatic cells only by treatment with small
molecules or manipulation of cell culture conditions while
overcoming potential risks.
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